Related Experiment Video

Updated: May 25, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis

Robert L Yauch1, Jeff Settleman

  • 1Discovery Oncology, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA.

Current Opinion in Genetics & Development
|February 11, 2012
PubMed

Insights

Personalized cancer medicine advances, including targeted therapies like ALK inhibitors and BRAF inhibitors, show promise. However, overcoming acquired drug resistance is crucial for long-term patient benefit.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Personalized cancer medicine, guided by tumor genotyping, has seen significant advancements.
  • FDA approvals of targeted therapies like crizotinib (ALK inhibitor) and vemurafenib (BRAF inhibitor) mark a new era in cancer treatment.
  • Acquired drug resistance presents a major challenge to the sustained efficacy of these tailored therapies.

Purpose of the Study:

  • To review recent progress in personalized cancer medicine.
  • To discuss the clinical utility of pathway-targeted cancer drug therapies.
  • To highlight the challenge of acquired drug resistance and future directions.

Main Methods:

  • Literature review of recent developments in targeted cancer therapy.
  • Analysis of FDA-approved targeted drugs and their clinical outcomes.
  • Discussion of mechanisms of acquired drug resistance.

Main Results:

  • Targeted therapies targeting specific genetic alterations (e.g., ALK translocations, BRAF mutations) have shown significant clinical benefits.
  • Examples include crizotinib for ALK-positive lung cancer and vemurafenib for BRAF-mutant melanoma.
  • Acquired resistance limits the durability of response to these targeted agents.

Conclusions:

  • Personalized cancer medicine has entered a new phase with targeted therapies.
  • Overcoming acquired drug resistance is essential for maximizing long-term patient benefit.
  • Future research should focus on strategies to optimize the clinical utility of these pathway-targeted therapies.

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...